IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Investor Presentation
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IOL Chemicals and Pharmaceuticals shared its Q1 FY26 investor presentation showing revenue from operations of ₹551.7 crore, up 9.8% year-on-year. EBITDA rose 19.5% to ₹69.5 crore with margins expanding to 12.4% (from 11.4% a year ago), while profit after tax grew 14.4% to ₹34.0 crore. The company received REACH certification for Acetic Anhydride, enabling EU exports, and won an EcoVadis Silver Medal for sustainability. It announced a ₹5.5 crore Minoxidil expansion (Unit 9B, 120 MTPA) targeted for December 2025 and acquired 101 acres near its existing facility for future growth. Exports contributed 75.6% of Q1 revenue, and the non-Ibuprofen pharma share has grown from 18% to 34% over five years, with management targeting export share to rise to ~40%.
Strong Q1 performance with margin expansion, low debt (D/E of 0.07), and visible capacity expansion plans signal healthy growth momentum for shareholders. New EU certifications and product diversification reduce dependence on Ibuprofen, supporting long-term earnings stability.